Literature DB >> 20082317

Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line.

Sang-Lin Li1, Feng Ye, Wei-Jun Cai, Huai-Dong Hu, Peng Hu, Hong Ren, Fu-Fan Zhu, Da-Zhi Zhang.   

Abstract

In order to understand the molecular mechanisms of multidrug resistance (MDR) in ovarian cancer, we employed the proteomic approach of isobaric tags for relative and absolute quantification (iTRAQ), followed by LC-MS/MS, using the cisplatin-resistant COC1/DDP cell line and its parental COC1 cell line as a model. A total number of 28 proteins differentially expressed were identified, and then the differential expression levels of partially identified proteins were confirmed by Western blot analysis and/or real-time RT-PCR. Furthermore, the association of PKM2 and HSPD1, two differentially expressed proteins, with MDR were analyzed, and the results showed that they could contribute considerably to the cisplatin resistance in ovarian cancer cell. The differential expression proteins could be classified into eight categories based on their functions, that is, calcium binding proteins, chaperones, extracellular matrix, proteins involved in drug detoxification or repair of DNA damage, metabolic enzymes, transcription factor, proteins related to cellular structure and proteins relative to signal transduction. These data will be valuable for further study of the mechanisms of MDR in the ovarian cancer. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20082317     DOI: 10.1002/jcb.22413

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  19 in total

Review 1.  Proteomics of ovarian cancer: functional insights and clinical applications.

Authors:  Mohamed A Elzek; Karin D Rodland
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

2.  Identification of DJ-1 as a contributor to multidrug resistance in human small-cell lung cancer using proteomic analysis.

Authors:  Hongyi Gao; Yuchun Niu; Man Li; Shun Fang; Linlang Guo
Journal:  Int J Exp Pathol       Date:  2017-06-05       Impact factor: 1.925

3.  Proteomic analysis identified DJ-1 as a cisplatin resistant marker in non-small cell lung cancer.

Authors:  Hua-Zong Zeng; Yi-Qing Qu; Wen-Jun Zhang; Bing Xiu; An-Mei Deng; Ai-Bin Liang
Journal:  Int J Mol Sci       Date:  2011-06-01       Impact factor: 5.923

4.  Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer.

Authors:  Elisabet Hjerpe; Suzanne Egyhazi Brage; Joseph Carlson; Marianne Frostvik Stolt; Kjell Schedvins; Hemming Johansson; Maria Shoshan; Elisabeth Avall-Lundqvist
Journal:  BMC Clin Pathol       Date:  2013-11-19

5.  High Expression of Pyruvate Kinase M2 is Associated with Chemosensitivity to Epirubicin and 5-Fluorouracil in Breast Cancer.

Authors:  Yang Lin; Feng Lv; Fangfang Liu; Xiaojing Guo; Yu Fan; Feng Gu; Jun Gu; Li Fu
Journal:  J Cancer       Date:  2015-09-15       Impact factor: 4.207

6.  Knockdown of the M2 Isoform of Pyruvate Kinase (PKM2) with shRNA Enhances the Effect of Docetaxel in Human NSCLC Cell Lines In Vitro.

Authors:  Sujuan Yuan; Tiankui Qiao; Xibing Zhuang; Wei Chen; Na Xing; Qi Zhang
Journal:  Yonsei Med J       Date:  2016-11       Impact factor: 2.759

Review 7.  Quantitative proteomics characterization of cancer biomarkers and treatment.

Authors:  Xiao-Li Yang; Yi Shi; Dan-Dan Zhang; Rui Xin; Jing Deng; Ting-Miao Wu; Hui-Min Wang; Pei-Yao Wang; Ji-Bin Liu; Wen Li; Yu-Shui Ma; Da Fu
Journal:  Mol Ther Oncolytics       Date:  2021-04-20       Impact factor: 7.200

Review 8.  Targeting cellular metabolism to improve cancer therapeutics.

Authors:  Y Zhao; E B Butler; M Tan
Journal:  Cell Death Dis       Date:  2013-03-07       Impact factor: 8.469

Review 9.  Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture.

Authors:  Debasish Paul; Avinash Kumar; Akshada Gajbhiye; Manas K Santra; Rapole Srikanth
Journal:  Biomed Res Int       Date:  2013-03-17       Impact factor: 3.411

10.  Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells.

Authors:  Verena Paulitschke; Verena Haudek-Prinz; Johannes Griss; Walter Berger; Thomas Mohr; Hubert Pehamberger; Rainer Kunstfeld; Christopher Gerner
Journal:  J Proteome Res       Date:  2013-06-19       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.